Osteopontin binds ICOSL promoting tumor metastasis

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Inducible T-cell costimulator ligand (ICOSL) and its receptor ICOS are key immune checkpoint molecules.
• Their interaction mediates immune responses with implications for anti-tumor activity.
• Osteopontin (OPN) is a pleiotropic cytokine involved in various physiological and pathological processes.

Purpose of the Study:

• To identify novel ligands for ICOSL.
• To investigate the functional consequences of OPN binding to ICOSL.
• To explore the role of the ICOSL-OPN interaction in tumor progression.

Main Methods:

• In vitro binding assays to confirm OPN as an ICOSL ligand.
• Cell migration and anchorage-independent growth assays.
• In vivo studies using the 4T1 breast cancer mouse model.

Main Results:

• Osteopontin (OPN) was identified as a novel ligand for ICOSL, binding to a different domain than ICOS.
• OPN binding to ICOSL induced a conformational change in OPN, exposing functional domains.
• In vitro, OPN-ICOSL interaction promoted cell migration and inhibited anchorage-independent growth.
• In vivo, OPN-triggered ICOSL signaling enhanced angiogenesis and tumor metastasis in a mouse breast cancer model.

Conclusions:

• Osteopontin is a novel ligand for ICOSL, modulating its function beyond the known ICOS interaction.
• The OPN-ICOSL axis plays a significant role in promoting tumor cell migration, angiogenesis, and metastasis.
• Targeting the ICOSL-OPN interaction presents a potential therapeutic strategy for cancer treatment.